Insulin Signaling and the Regulation of Glucose Transport. Because overexpression of CAPΔSH3 blocked TC10 activation by insulin. Insulin stimulates glycogen synthase by inhibiting glycogen synthase kinases or/and activating protein phosphatase 1 (PP1) among other mechanisms. [19] Model organisms [ edit ]. Olive Oil and Other Plant-Derived Oils. Butter Two tbsp. Butter, about 1 ounce, contain 22 grams of fat and no carbohydrates or protein. The other 6 grams in the 28 grams ounces of butter is made up mostly of water, along with a small amount of milk solids. Butter eaten by itself does not stimulate the release of insulin.
Abstract
The epidemic of type 2 diabetes and impaired glucose tolerance is one of the main causes of morbidity and mortality worldwide. In both disorders, tissues such as muscle, fat and liver become less responsive or resistant to insulin. This state is also linked to other common health problems, such as obesity, polycystic ovarian disease, hyperlipidaemia, hypertension and atherosclerosis. The pathophysiology of insulin resistance involves a complex network of signalling pathways, activated by the insulin receptor, which regulates intermediary metabolism and its organization in cells. But recent studies have shown that numerous other hormones and signalling events attenuate insulin action, and are important in type 2 diabetes.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
All prices include VAT for Germany.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1Klip, A. & Paquet, M. R. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care13, 228–243 (1990).
- 2Bruning, J. C. et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell2, 559–569 (1998).
- 3Abel, E. D. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature409, 729–733 (2001).
- 4Gavrilova, O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest.105, 271–278 (2000).
- 5Kulkarni, R. N. et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell96, 329–339 (1999).
- 6Patti, M. E. & Kahn, C. R. The insulin receptor—a critical link in glucose homeostasis and insulin action. J. Basic Clin. Physiol. Pharmacol.9, 89–109 (1998).
- 7Butler, A. A. & LeRoith, D. Tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology142, 1685–1688 (2001).
- 8Skorokhod, A. et al. Origin of insulin receptor-like tyrosine kinases in marine sponges. Biol. Bull.197, 198–206 (1999).
- 9White, M. F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem.182, 3–11 (1998).
- 10Pessin, J. E. & Saltiel, A. R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest.106, 165–169 (2000).
- 11Tamemoto, H. et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature372, 182–186 (1994).
- 12Araki, E. et al. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. Nature372, 186–190 (1994).
- 13Kido, Y. et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J. Clin. Invest.105, 199–205 (2000).
- 14Withers, D. J. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature391, 900–904 (1998).
- 15Fantin, V. R., Wang, Q., Lienhard, G. E. & Keller, S. R. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am. J. Physiol. Endocrinol. Metab.278, E127–E133 (2000).
- 16Fasshauer, M. et al. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol. Cell. Biol.21, 319–329 (2001).
- 17Mendez, R., Myers, M. G. Jr, White, M. F. & Rhoads, R. E. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell. Biol.16, 2857–2864 (1996).
- 18Tsuruzoe, K., Emkey, R., Kriauciunas, K. M., Ueki, K. & Kahn, C. R. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol. Cell. Biol.21, 26–38 (2001).
- 19Hotamisligil, G. S. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science271, 665–668 (1996).
- 20Craparo, A., Freund, R. & Gustafson, T. A. 14-3-3 (ɛ) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J. Biol. Chem.272, 11663–11669 (1997).
- 21Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science293, 1673–1677 (2001).
- 22Kim, J. K. et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest.108, 437–446 (2001).
- 23Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science283, 1544–1548 (1999).
- 24Shepherd, P. R., Nave, B. T. & Siddle, K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem. J.305, 25–28 (1995).
- 25Myers, M. G. Jr et al. IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc. Natl Acad. Sci. USA89, 10350–10354 (1992).
- 26Pons, S. et al. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol. Cell. Biol.15, 4453–4465 (1995).
- 27Antonetti, D. A., Algenstaedt, P. & Kahn, C. R. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol. Cell. Biol.16, 2195–2203 (1996).
- 28Fruman, D. A., Cantley, L. C. & Carpenter, C. L. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics37, 113–121 (1996).
- 29Kerouz, N. J., Horsch, D., Pons, S. & Kahn, C. R. Differential regulation of insulin receptor substrates-1 and-2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest.100, 3164–3172 (1997).
- 30Fruman, D. A. et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85α. Nature Genet.26, 379–382 (2000).
- 31Terauchi, Y. et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nature Genet.21, 230–235 (1999).
- 32Lietzke, S. E. et al. Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol. Cell6, 385–394 (2000).
- 33Kessler, A., Uphues, I., Ouwens, D. M., Till, M. & Eckel, J. Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. Am. J. Physiol. Endocrinol. Metab.280, E65–E74 (2001).
- 34Peterson, R. T. & Schreiber, S. L. Kinase phosphorylation: keeping it all in the family. Curr. Biol.9, R521–R524 (1999).
- 35Mackay, D. J. & Hall, A. Rho GTPases. J. Biol. Chem.273, 20685–20688 (1998).
- 36Ziegler, S. F., Bird, T. A., Schneringer, J. A., Schooley, K. A. & Baum, P. R. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene8, 663–670 (1993).
- 37Alessi, D. R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol.7, 261–269 (1997).
- 38Cross, D. A. et al. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem. J.303, 21–26 (1994).
- 39Nakae, J., Park, B. C. & Accili, D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J. Biol. Chem.274, 15982–15985 (1999).
- 40Brady, M. J., Bourbonais, F. J. & Saltiel, A. R. The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells. J. Biol. Chem.273, 14063–14066 (1998).
- 41Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science292, 1728–1731 (2001).
- 42Standaert, M. L. et al. Protein kinase C-ζ as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J. Biol. Chem.272, 30075–30082 (1997).
- 43Ogg, S. & Ruvkun, G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell2, 887–893 (1998).
- 44Wada, T. et al. Role of the Src homology 2 (SH2) domain and C-terminus tyrosine phosphorylation sites of SH2-containing inositol phosphatase (SHIP) in the regulation of insulin-induced mitogenesis. Endocrinology140, 4585–4594 (1999).
- 45Clement, S. et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature409, 92–97 (2001).
- 46Ribon, V. & Saltiel, A. R. Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. Biochem. J.324, 839–845 (1997).
- 47Ribon, V., Herrera, R., Kay, B. K. & Saltiel, A. R. A role for CAP, a novel, multifunctional Src homology 3 domain-containing protein in formation of actin stress fibers and focal adhesions. J. Biol. Chem.273, 4073–4080 (1998).
- 48Ribon, V., Johnson, J. H., Camp, H. S. & Saltiel, A. R. Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc. Natl Acad. Sci. USA95, 14751–14756 (1998).
- 49Kimura, A., Baumann, C. A., Chiang, S. H. & Saltiel, A. R. The sorbin homology domain: a motif for the targeting of proteins to lipid rafts. Proc. Natl Acad. Sci. USA98, 9098–9103 (2001).
- 50Baumann, C. A. et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature407, 202–207 (2000).
- 51Chiang, S. H. et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature410, 944–948 (2001).
- 52Watson, R. T. et al. Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. J. Cell Biol.154, 829–840 (2001).
- 53Boulton, T. G. et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell65, 663–675 (1991).
- 54Lazar, D. F. et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem.270, 20801–20807 (1995).
- 55Raught, B., Gingras, A. C. & Sonenberg, N. The target of rapamycin (TOR) proteins. Proc. Natl Acad. Sci. USA98, 7037–7044 (2001).
- 56Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R. & Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J.344, 427–431 (1999).
- 57Thomas, G. & Hall, M. N. TOR signalling and control of cell growth. Curr. Opin. Cell Biol.9, 782–787 (1997).
- 58Miron, M. et al. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nature Cell Biol.3, 596–601 (2001).
- 59Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature378, 785–789 (1995).
- 60Brady, M. J., Nairn, A. C. & Saltiel, A. R. The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes. Evidence for a potential role for DARPP-32 in insulin action. J. Biol. Chem.272, 29698–29703 (1997).
- 61Newgard, C. B., Brady, M. J., O'Doherty, R. M. & Saltiel, A. R. Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes49, 1967–1977 (2000).
- 62Michael, M. D. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell6, 87–97 (2000).
- 63Bergman, R. N. & Ader, M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol. Metab.11, 351–356 (2000).
- 64Bergman, R. N. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog. Horm. Res.52, 359–385 (1997).
- 65Pilkis, S. J. & Granner, D. K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol.54, 885–909 (1992).
- 66Sutherland, C., O'Brien, R. M. & Granner, D. K. New connections in the regulation of PEPCK gene expression by insulin. Phil. Trans. R. Soc. Lond. B351, 191–199 (1996).
- 67Yoon, J. C. et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature413, 131–138 (2001).
- 68Shimomura, I. et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA96, 13656–13661 (1999).
- 69Foretz, M. et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol. Cell. Biol.19, 3760–3768 (1999).
- 70Shimomura, I. et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell6, 77–86 (2000).
- 71Anthonsen, M. W., Ronnstrand, L., Wernstedt, C., Degerman, E. & Holm, C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J. Biol. Chem.273, 215–221 (1998).
- 72Kitamura, T. et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell. Biol.19, 6286–6296 (1999).
- 73Cusi, K. et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest.105, 311–320 (2000).
- 74Taylor, S. I. & Arioglu, E. Syndromes associated with insulin resistance and acanthosis nigricans. J. Basic Clin. Physiol. Pharmacol.9, 419–439 (1998).
- 75Stern, M. P. Strategies and prospects for finding insulin resistance genes. J. Clin. Invest.106, 323–327 (2000).
- 76Bruning, J. C. et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell88, 561–572 (1997).
- 77Terauchi, Y. et al. Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and β cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. J. Clin. Invest.99, 861–866 (1997).
- 78Kulkarni, R. N. et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J. Clin. Invest.104, R69–R75 (1999).
- 79Bruning, J. C. et al. Role of brain insulin receptor in control of body weight and reproduction. Science289, 2122–2125 (2000).
- 80Zisman, A. et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nature Med.6, 924–928 (2000).
- 81Katz, E. B., Stenbit, A. E., Hatton, K., DePinho, R. & Charron, M. J. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature377, 151–155 (1995).
- 82Kim, J. K. et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest.105, 1791–1797 (2000).
- 83Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest.106, 171–176 (2000).
- 84Hwang, J. H., Pan, J. W., Heydari, S., Hetherington, H. P. & Stein, D. T. Regional differences in intramyocellular lipids in humans observed by in vivo 1H-MR spectroscopic imaging. J. Appl. Physiol.90, 1267–1274 (2001).
- 85Kim, J. K. et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl Acad. Sci. USA98, 7522–7527 (2001).
- 86Ventre, J. et al. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes46, 1526–1531 (1997).
- 87Ofei, F., Hurel, S., Newkirk, J., Sopwith, M., Taylor, R. Effects of an engineered human anti-TNF-alpha antibody (SDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes45, 881–885 (1996).
- 88Halaas, J. L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science269, 543–546 (1995).
- 89Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S. & Goldstein, J. L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature401, 73–76 (1999).
- 90Lee, Y. et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J. Biol. Chem.276, 5629–5635 (2001).
- 91Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA98, 2005–2010 (2001).
- 92Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med.7, 941–946 (2001).
- 93Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med.7, 947–953 (2001).
- 94Vionnet, N. et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am. J. Hum. Genet.67, 1470–1480 (2000).
- 95Steppan, C. M. et al. A family of tissue-specific resistin-like molecules. Proc. Natl Acad. Sci. USA98, 502–506 (2001).
- 96Nagaev, I. & Smith, U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun.285, 561–564 (2001).
- 97Accili, D., Nakae, J., Kim, J. J., Park, B. C. & Rother, K. I. Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J. Pediatr. Endocrinol. Metab.12, 475–485 (1999).
- 98Postic, C. et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem.274, 305–315 (1999).
- 99Pessin, J. E., Thurmond, D. C., Elmendorf, J. S., Coker, K. J. & Okada, S. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J. Biol. Chem.274, 2593–2596 (1999).
- 100Guilherme, A. et al. Perinuclear localization and insulin responsiveness of GLUT4 requires cytoskeletal integrity in 3T3-L1 adipocytes. J. Biol. Chem.275, 38151–38159 (2000).
Acknowledgements
![Does Does](/uploads/1/2/6/1/126172376/448908865.jpg)
We apologize to the many investigators whose work we could not cite owing to a limit on the number of references.
Author information
Rights and permissions
About this article
Issue Date
DOI
Further reading
Loss of the glucocorticoid receptor in zebrafish improves muscle glucose availability and increases growth
American Journal of Physiology-Endocrinology and Metabolism (2019)The role of ERp44 in glucose and lipid metabolism
Archives of Biochemistry and Biophysics (2019)MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway
Cell Death & Disease (2019)Ishige okamurae Extract Ameliorates the Hyperglycemia and Body Weight Gain of db/db Mice through Regulation of the PI3K/Akt Pathway and Thermogenic Factors by FGF21
Marine Drugs (2019)Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective
JACC: Basic to Translational Science (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
Article metrics
Citations
Does Insulin Activate Glycolysis
2946
More details
Insulin and glucagon are hormones that help regulate the levels of blood glucose, or sugar, in your body. Glucose, which comes from the food you eat, moves through your bloodstream to help fuel your body.
Insulin and glucagon work together to balance your blood sugar levels, keeping them in the narrow range that your body requires. These hormones are like the yin and yang of blood glucose maintenance. Read on to learn more about how they function and what can happen when they don’t work well.
Insulin and glucagon work in what’s called a negative feedback loop. During this process, one event triggers another, which triggers another, and so on, to keep your blood sugar levels balanced.
How insulin works
During digestion, foods that contain carbohydrates are converted into glucose. Most of this glucose is sent into your bloodstream, causing a rise in blood glucose levels. This increase in blood glucose signals your pancreas to produce insulin.
The insulin tells cells throughout your body to take in glucose from your bloodstream. As the glucose moves into your cells, your blood glucose levels go down. Some cells use the glucose as energy. Other cells, such as in your liver and muscles, store any excess glucose as a substance called glycogen. Your body uses glycogen for fuel between meals.
How glucagon works
Glucagon works to counterbalance the actions of insulin.
About four to six hours after you eat, the glucose levels in your blood decrease, triggering your pancreas to produce glucagon. This hormone signals your liver and muscle cells to change the stored glycogen back into glucose. These cells then release the glucose into your bloodstream so your other cells can use it for energy.
This whole feedback loop with insulin and glucagon is constantly in motion. It keeps your blood sugar levels from dipping too low, ensuring that your body has a steady supply of energy.
Term | Definition |
glucose | sugar that travels through your blood to fuel your cells |
insulin | a hormone that tells your cells either to take glucose from your blood for energy or to store it for later use |
glycogen | a substance made from glucose that’s stored in your liver and muscle cells to be used later for energy |
glucagon | a hormone that tells cells in your liver and muscles to convert glycogen into glucose and release it into your blood so your cells can use it for energy |
pancreas | an organ in your abdomen that makes and releases insulin and glucagon |
Your body’s regulation of blood glucose is an amazing metabolic feat. However, for some people, the process doesn’t work properly. Diabetes mellitus is the best known condition that causes problems with blood sugar balance.
Diabetes refers to a group of diseases. If you have diabetes or prediabetes, your body’s use or production of insulin and glucagon are off. And when the system is thrown out of balance, it can lead to dangerous levels of glucose in your blood.
Type 1 diabetes
Of the two main types of diabetes, type 1 diabetes is the less common form. It’s thought to be an autoimmune disorder in which your immune system destroys the cells that make insulin in your pancreas. If you have type 1 diabetes, your pancreas doesn’t produce insulin. As a result, you must take insulin every day. If you don’t, you’ll get very sick or you could die. For more information, read about the complications of type 1 diabetes.
Type 2 diabetes
With type 2 diabetes, your body makes insulin but your cells don’t respond to it normally. They don’t take in glucose from your bloodstream as well as they once did, which leads to higher blood sugar levels. Over time, type 2 diabetes makes your body produce less insulin, which further raises your blood sugar levels.
Gestational diabetes
Some women develop gestational diabetes late in their pregnancies. In gestational diabetes, pregnancy-related hormones may interfere with how insulin works. This condition normally disappears after the pregnancy ends. However, if you’ve had gestational diabetes, you’re at greater risk of developing type 2 diabetes in the future.
Prediabetes
How Does Insulin Activate Pp1
If you have prediabetes, your body makes insulin but doesn’t use it properly. As a result, your blood glucose levels are raised, though not as high as they would be if you had type 2 diabetes. Many people who have prediabetes go on to develop type 2 diabetes.
Knowing how your body works can help you stay healthy. Insulin and glucagon are two critical hormones your body makes to keep your blood sugar levels balanced. It’s helpful to understand how these hormones function so you can work to avoid diabetes.
If you have more questions about insulin, glucagon, and blood glucose, talk to your doctor. Questions you have might include:
- Is my blood glucose at a safe level?
- Do I have prediabetes?
- What can I do to avoid developing diabetes?
- How do I know if I need to take insulin?